Literature DB >> 24390994

Differences in frequencies of UGT1A9, 1A7, and 1A1 genetic polymorphisms in Chinese Tibetan versus Han Chinese populations.

W Yan1, Y W Wang, F F Yang, M Wang, X Q Zhang, J Dong, E Chen, J Yang.   

Abstract

As part of a series of pharmacogenomics studies of the Chinese population, we investigated genetic polymorphisms of some UGT1A regions. The three genes that were analyzed were UGT1A9, 1A7, and 1A1; we sequenced their exons, together with promoters, surrounding introns and 3'-untranslated regions (3'UTR) in 100 unrelated-healthy Chinese Tibetan individuals. We compared the data with information on Han Chinese of the same region, which we downloaded from the HapMap database. We identified 40 polymorphisms; 16 of them were shared by the two populations. We then analyzed their linkage disequilibrium map. The UGT1As cluster can be divided into two linkage blocks in the Tibetan population: Block 1 (UGT1A9, UGT1A7), Block 2 (3'-UTR). Furthermore, we identified haplotypes and selected their tagSNPs. In exon 1 of UGT1A7 gene, 393G>A (Arg131Gln, rs17868324) was found at a frequency of 44.4% in the Tibetan population, compared to only 0.7% in the Han population. The linkage blocks in the Han Chinese sample differed from that of the Chinese Tibetan group; the former had Block 1 (UGT1A9, UGT1A7), Block 2 (UGT1A7), and Block 3 (3'-UTR). These findings provide fundamental information for future molecular genetic studies of the UGT1A gene cluster as well as for personalized medicine in Chinese.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24390994     DOI: 10.4238/2013.December.10.6

Source DB:  PubMed          Journal:  Genet Mol Res        ISSN: 1676-5680


  3 in total

1.  Impact of clinical factors and UGT1A9 and CYP2B6 genotype on inter-individual differences in propofol pharmacokinetics.

Authors:  Akihiro Kanaya; Toshihiro Sato; Nobuo Fuse; Hiroaki Yamaguchi; Nariyasu Mano; Masanori Yamauchi
Journal:  J Anesth       Date:  2018-02-21       Impact factor: 2.078

2.  Comparison of UGT1A1 Polymorphism as Guidance of Irinotecan Dose Escalation in RAS Wild-Type Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab Plus FOLFIRI as the First-Line Therapy.

Authors:  Hsiang-Lin Tsai; Yen-Cheng Chen; Tzu-Chieh Yin; Wei-Chih Su; Po-Jung Chen; Tsung-Kun Chang; Ching-Chun Li; Ching-Wen Huang; Jaw-Yuan Wang
Journal:  Oncol Res       Date:  2022-02-17       Impact factor: 4.938

3.  Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.

Authors:  Shaojun Chen; Li Hua; Chengjun Feng; Qia Mo; Mengzhuan Wei; Yongqi Shen; Zhan Lin; Guisheng Li; Junyi Xu; Chengxian Guo; Haixin Huang
Journal:  BMC Gastroenterol       Date:  2020-04-07       Impact factor: 3.067

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.